catalpol has been researched along with Diabetic Nephropathies in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, Y; Du, Q; Fu, Y; Jiang, M; Jiao, N; Liu, L; Sun, J; Wu, H; Xu, H; Zhu, Y | 1 |
| Chen, J; Chen, Y; Du, Q; Lv, Z; Shu, A; Wang, W; Xu, H; Yang, Y | 1 |
| Bhattamisra, SK; Choudhury, H; Koh, HM; Lim, SY; Pandey, M | 1 |
| Chen, J; Chen, Y; Du, Q; Gao, Y; Lu, J; Lv, G; Shu, A; Xu, H; Zhu, Y | 1 |
| Chen, CX; Dong, Z | 1 |
| Deng, H; Jin, X; Ling, Z; Liu, M; Ma, Y; Shan, Q; Tang, J; Wei, Q; Xie, J; Yang, S; Zeng, H; Zhang, Q | 1 |
1 review(s) available for catalpol and Diabetic Nephropathies
| Article | Year |
|---|---|
Molecular and Biochemical Pathways of Catalpol in Alleviating Diabetes Mellitus and Its Complications.
Topics: Animals; Antioxidants; Cell Differentiation; Cell Proliferation; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; Homeostasis; Humans; Hypoglycemic Agents; Iridoid Glucosides; Liver; Mice; Muscle, Skeletal; Neurodegenerative Diseases; NF-kappa B; NF-kappa B p50 Subunit; Osteoblasts; Pancreas; Phosphatidylinositol 3-Kinases; Phosphoenolpyruvate Carboxykinase (ATP); Rehmannia; Retina; Signal Transduction | 2021 |
5 other study(ies) available for catalpol and Diabetic Nephropathies
| Article | Year |
|---|---|
Loganin and catalpol exert cooperative ameliorating effects on podocyte apoptosis upon diabetic nephropathy by targeting AGEs-RAGE signaling.
Topics: Animals; Apoptosis; Diabetic Nephropathies; Drug Therapy, Combination; Glycation End Products, Advanced; Iridoid Glucosides; Iridoids; Male; Mice; Mice, Inbred C57BL; NADPH Oxidase 4; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Podocytes; Receptor for Advanced Glycation End Products; Signal Transduction | 2020 |
Study on the inhibitive effect of Catalpol on diabetic nephropathy.
Topics: AMP-Activated Protein Kinases; Animals; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme-Linked Immunosorbent Assay; Hypoglycemic Agents; Iridoid Glucosides; Kidney; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Oxidative Stress; Signal Transduction; Sirtuin 1 | 2020 |
Catalpol ameliorates endothelial dysfunction and inflammation in diabetic nephropathy via suppression of RAGE/RhoA/ROCK signaling pathway.
Topics: Animals; Diabetic Nephropathies; Endothelium; Inflammation; Iridoid Glucosides; Macrophages; Mice; Receptor for Advanced Glycation End Products; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction | 2021 |
Effect of catalpol on diabetic nephropathy in rats.
Topics: Angiotensin II; Animals; Collagen Type IV; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drugs, Chinese Herbal; Fibronectins; Iridoid Glucosides; Kidney; Male; Organ Size; Phytotherapy; Random Allocation; Rats; Rats, Sprague-Dawley; Rehmannia; RNA, Messenger; Transforming Growth Factor beta1 | 2013 |
Amelioration of Diabetic Mouse Nephropathy by Catalpol Correlates with Down-Regulation of Grb10 Expression and Activation of Insulin-Like Growth Factor 1 / Insulin-Like Growth Factor 1 Receptor Signaling.
Topics: Animals; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Down-Regulation; Drugs, Chinese Herbal; Gene Expression; GRB10 Adaptor Protein; Hypoglycemic Agents; Insulin-Like Growth Factor I; Iridoid Glucosides; Kidney; Male; Mice; Mice, Inbred C57BL; Polymerase Chain Reaction; Receptor, IGF Type 1 | 2016 |